3B Pharmaceuticals has announced a multi-year collaboration with Boehringer Ingelheim, for peptide-led drug discovery.
Under the terms of the deal, Boehringer will choose a set of molecular disease targets on which 3B Pharmaceuticals will employ its high-diversity peptide library and hit identification technology.
Hit compounds identified will be further optimised and jointly characterised by both companies.
Dr Ulrich Reineke, managing director of 3BP, said in a statement: “We are very pleased to substantially broaden our relationship with Boehringer Ingelheim and confident in adding significant value through our validated peptide hit discovery and medicinal chemistry capabilities.”
As a leader in peptide discovery and optimisation, 3B Pharmaceuticals has built a technology platform extending from hit identification to early clinical development, which Boehringer will further enable them to develop.
